In order to obtain direct evidence that endotoxin-induced tumor regression is based on T cell-mediated, concomitant antitumor immunity, it was shown, first, that the rise and fall of susceptibility of the SA-1 sarcoma to endotoxin treatments (50 microgram intravenously) corresponded exactIy to the generation and decay of the host's concomitant immune response to this tumor and that complete regression occurs onIy when endotoxin is given at the peak of concomitant immunity on day 9 to 10. Secondly, it was shown that endotoxin fails to cause the regression of the SA-1 sarcoma growing in mice that are incapable of generating concomitant immunity because of having been made T-cell deficient (TXB mice) by thymectomy and lethal irradiation and restored with bone marrow. Most importantly, it also was shown that endotoxin causes the complete regression of large SA-1 tumors growing in TXB recipients provided these recipients are given spleen cells from immunocompetent 9-day tumor-bearing donors, i.e., from donors with peak concomitant immunity and, therefore, with susceptible tumors. The spleen cells from tumor-bearing donors that mediate endotoxin-induced tumor regression in TXB recipients are destroyed by monoclonal anti-Thy-1.2, or anti-Ly-2.2 antibody and complement, but not by anti-Ly-1.2 antibody and complement. This represents unequivocal direct evidence that endotoxin-induced tumor regression is based on a T-cell-mediated immune response to tumor-associated transplantation antigens. Reciprocal passive transfer experiments with the SA1 and a benzpyrene-induced fibrosarcoma have revealed, in addition, that the mediation of endotoxin-induced regression is specific. It can be hypothesized, therefore, that endotoxin and other agents that are capable of causing the regression of already established immunogenic tumors are immunofaciIitators rather than immunopotentiators in that they facilitate the expression of an already acquired state of concomitant immunity. Results obtained thus far with Poly I:C show that the antitumor properties of this compound likewise are based on its capacity to facilitate the expression of an acquired state of concomitant immunity. It can be predicted from this hypothesis that any manipulation that augments concomitant antitumor immunity will make a tumor more susceptible to the antitumor action of endotoxin and Poly I:C. (TA)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA027794-05
Application #
3167826
Study Section
Experimental Immunology Study Section (EI)
Project Start
1980-12-01
Project End
1986-08-31
Budget Start
1984-12-01
Budget End
1986-08-31
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Trudeau Institute, Inc.
Department
Type
DUNS #
City
Saranac Lake
State
NY
Country
United States
Zip Code
12983
Rakhmilevich, A L (1994) Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection. Transplantation 58:72-80
Rakhmilevich, A L; North, R J (1994) Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol Immunother 38:107-12
Rakhmilevich, A L; North, R J; Dye, E S (1993) Evidence inconsistent with a role for tumor necrosis factor in tumor allograft rejection. Transplantation 55:182-6
Rakhmilevich, A L; North, R J; Dye, E S (1993) Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int J Cancer 55:338-43
North, R J; Dunn, P L; Havell, E A (1991) A role for tumor necrosis factor in poly(I:C)-induced hemorrhagic necrosis and T-cell-dependent regression of a murine sarcoma. J Interferon Res 11:333-40
Rakhmilevich, A L; North, R J (1991) Rapid acquisition of an enhanced capacity to produce tumor necrosis factor, alpha/beta interferon, and interleukin 6 after implantation of tumor cells. Cytokine 3:398-406
Dunn, P L; North, R J (1991) Effect of advanced ageing on the ability of mice to cause tumour regression in response to immunotherapy. Immunology 74:355-9
Dunn, P L; North, R J (1991) Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells. Cancer Immunol Immunother 33:421-3
Dunn, P L; North, R J (1991) Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukoc Biol 49:388-96
North, R J; Awwad, M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90-5

Showing the most recent 10 out of 27 publications